Comparison of Ultrathin-Strut Sirolimus-Eluting Stents Versus Drug-Coated Balloons in Small Coronary Vessels: Real-World Data
Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · 2026
DOI: 10.5543/tkda.2025.29797 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology, 2026. Verfasst von Berhan Keskin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Sirolimus, Coronary Artery Disease, Percutaneous Coronary Intervention.
Abstract (Originalsprache)
Objective
Drug-coated balloons (DCBs) and ultrathin-strut sirolimus-eluting stents (SES) are both treatment options for small-vessel coronary artery disease. However, comparative real-world data between these strategies are limited.
Method
In this single-center retrospective study, 178 consecutive patients with stable angina who underwent percutaneous coronary intervention with either a DCB (n = 89) or an ultrathin-strut SES (n = 89) between January 2017 and May 2025 were analyzed. Baseline demographics, angiographic and procedural features, and clinical outcomes were assessed. The primary outcome of this study was major adverse cardiac events (MACE), defined as a composite of target-lesion revascularization (TLR), long-term all-cause mortality, stroke, and myocardial infarction.
Results
Baseline characteristics were generally comparable, although SES-treated patients were older and had higher SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) scores. During a median follow-up of 293 days, MACE occurred in 2.2% of the DCB group and 5.6% of the SES group (P = 0.441). Rates of TLR, myocardial infarction, bleeding, and all-cause mortality were not significantly different. Kaplan–Meier analysis likewise demonstrated no significant difference in cumulative MACE between the two groups (log-rank P = 0.068).
Conclusion
In this real-world study, DCB treatment demonstrated similar safety and efficacy compared to ultrathin-strut SES for small-vessel coronary artery disease. DCB therapy may represent a viable alternative to DES in selected patients, supporting the “leave nothing behind” strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Istanbul Medipol University, Medipol Mega University Hospital, Istanbul, Türkiye.
Zitieren
APA
Keskin, B., Hakgör, A., Dursun, A., Akhundova, A., Beşiroğlu, M., Çakal, B., Güneş, H. M., Karaca, O., Güler, E., Barutçu, İ., & Boztosun, B. (2026). Comparison of Ultrathin-Strut Sirolimus-Eluting Stents Versus Drug-Coated Balloons in Small Coronary Vessels: Real-World Data. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. https://doi.org/10.5543/tkda.2025.29797
Vancouver
Keskin B, Hakgör A, Dursun A, Akhundova A, Beşiroğlu M, Çakal B, et al. Comparison of Ultrathin-Strut Sirolimus-Eluting Stents Versus Drug-Coated Balloons in Small Coronary Vessels: Real-World Data. Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology. 2026. doi:10.5543/tkda.2025.29797
BibTeX
@article{Keskin2026,
author = {Keskin, Berhan and Hakgör, Aykun and Dursun, Atakan and Akhundova, Aysel and Beşiroğlu, Mehmet and Çakal, Beytullah and Güneş, Hacı Murat and Karaca, Oğuz and Güler, Ekrem and Barutçu, İrfan and Boztosun, Bilal},
title = {Comparison of Ultrathin-Strut Sirolimus-Eluting Stents Versus Drug-Coated Balloons in Small Coronary Vessels: Real-World Data},
journal = {Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology},
year = {2026},
doi = {10.5543/tkda.2025.29797}
}
EUVIMED